Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01356160 · ClinicalTrials.gov registry record · Phase 2

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

A Phase 2 study of Hepatitis C, Chronic, sponsored by Gilead Sciences.

Completed
Registry status
Phase 2
Development phase
351
Enrollment target
20
Study locations

NCT01356160 is a Phase 2 study of Hepatitis C, Chronic that has completed, run by Gilead Sciences. The registered enrollment target is 351 participants, roughly in line with the 363-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target. The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01356160, a Phase 2 study of Hepatitis C, Chronic, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 2
Development phase
351 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection.

Conditions Studied

Hepatitis C, Chronic

Interventions

  • DRUG GS-5885
  • DRUG GS-9451
  • BIOLOGICAL peginterferon alfa-2a
  • DRUG ribavirin tablet
  • DRUG GS-9451 Placebo

Study Locations (20)

California

  • - Beverly Hills
  • - Coronado
  • - Costa Mesa
  • - San Diego

Texas

  • - Arlington
  • - Houston
  • - San Antonio

Colorado

  • - Aurora
  • - Englewood

Maryland

  • - Baltimore
  • - Baltimore

New York

  • - Forest Hills
  • - Manhasset

Arizona

  • - Tucson

Florida

  • - Bradenton

Massachusetts

  • - Burlington

Trial Details

FieldValue
Enrollment Target 351 participants
Start Date 2011-07
Est. Completion 2013-06
Phase Phase 2

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01356160

The ClinicalTrials.gov registry entry for NCT01356160 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 363-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 5 interventions - of which GS-5885 is the first listed.

NCT01356160 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Texas, Colorado.

Frequently Asked Questions

What is clinical trial NCT01356160 about?

NCT01356160 is a clinical study titled "GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus". This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection.

What is the current status of trial NCT01356160?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 351 participants. The study started on 2011-07. Estimated completion is 2013-06.

What conditions does trial NCT01356160 study?

This clinical trial studies the following conditions: Hepatitis C, Chronic.

What interventions are being tested in trial NCT01356160?

The interventions under investigation include: GS-5885 (DRUG), GS-9451 (DRUG), peginterferon alfa-2a (BIOLOGICAL), ribavirin tablet (DRUG), GS-9451 Placebo (DRUG).

Who is sponsoring clinical trial NCT01356160?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01356160 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C, Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C, Chronic

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.